Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Madharry who wrote (901)	1/21/2002 5:06:18 PM
From: Icebrg	Read Replies (1) \| Respond to of 3044

Madharry I think this acquisition should be looked upon from Millennium's stated aspiration of becoming "The Biopharmaceutical of the Future". One might or might not approve of such goals. If one doesn't - one shouldn't hold the stock in the first place. Millennium is very well aware of the fact that they will not be able to fullfil their ambition, if they do not have a strong presence in the cardiac market segments. Therefore one should IMHO not look upon this transaction searching for immediate synergies, but look upon it as something of a shortcut to the required much stronger presence in the cardiac arena. MLNM has, as far as I have understood some very interesting early leads in this slot, and the access to Cor's expertise should help a lot in their future development work. Apart from everything else. I (somewhat naively perhaps) don't look for the dollars and cents rationale behind this transaction, but rather consider it to be a necessary step on the way to build the type of company they are aiming for. Ice

To: Madharry who wrote (901)	1/21/2002 5:30:36 PM
From: Elmer	Read Replies (2) \| Respond to of 3044

<i don't like it> No argument here. My only point is that I agree with what the article says. MLNM is buying CORR so that it will have the scale to avoid being a target itself two years out. Big Pharma will be looking for product based biotech stocks to acquire. MLNM is trying to get there first. OT: Page 44 of the proxy solicitation in Morgan Stanley's fairness opinion lists five Mid-cap Product-Based Biotech Companies. They include GILD, CEPH, ENZN, CELG and QLTI. Each of these companies will also be looking to do acquisitions to avoid being bought out by big Pharma. A strategy I may use is to buy these stock after their prices decline on future acquisition announcements or alternatively just buy their targets and wait for the exchange.